首页> 外文期刊>Research and practice in thrombosis and haemostasis. >Fully automated thromboelastograph TEG 6s to measure anticoagulant effects of direct oral anticoagulants in healthy male volunteers
【24h】

Fully automated thromboelastograph TEG 6s to measure anticoagulant effects of direct oral anticoagulants in healthy male volunteers

机译:全自动血栓弹力图TEG 6s在健康男性志愿者中测量直接口服抗凝剂的抗凝作用

获取原文
           

摘要

Background The ability to assess the hemostatic effect of the direct oral anticoagulant (DOACs) may be valuable in clinical situations such as bleeding or thrombosis, before urgent surgery, or reversal of anticoagulation. We sought to assess the anticoagulant effect of DOACs with the new‐generation fully automated thrombelastograph TEG 6s using resonance‐frequency viscoelasticity measurements and disposable multichannel microfluidic cartridges. Methods A single dose of oral dabigatran 150?mg, rivaroxaban 20?mg, or apixaban 5?mg was given to 9 healthy males. Phlebotomy was performed at 0, 1, and 3?hours after administration of DOAC. TEG parameters were measured using TEGsup_/sup6s. Concentrations of DOACs were measured using chromogenic assays. The TEG parameters were correlated to the DOAC concentrations. Results The reaction time (R) demonstrated the strongest response to DOAC intake. There were no correlations between other TEG parameters and DOAC concentrations. Using the direct thrombin inhibitor (DTI) channel, R was significantly correlated with dabigatran levels (r?=?0.94, P??0.0001). Using the anti–factor Xa (AFXa) channel, R was significantly correlated with rivaroxaban and apixaban levels (r?=?0.93 and r?=?0.83, respectively; P??0.0001 for both). R 2.5?minutes for dabigatran (DTI channel), 2.5?minutes for apixaban, and 1.8?minutes for rivaroxaban (AFXa channel) were associated with 100% sensitivity and?≥?90% specificity to detect DOAC levels of?≥?50?ng/mL. Conclusion We have demonstrated that TEGsup_/sup6s R has significant correlation with DOAC blood concentrations and has potential for monitoring the DOAC's effect on hemostasis with reasonable sensitivity in the small sample analyzed. This novel technology is easy to use on a small volume of whole blood without requiring a specialized laboratory. Further study is warranted to correlate R with clinical outcomes.
机译:背景技术评估直接口服抗凝剂(DOAC)止血作用的能力在临床情况下很有价值,例如出血或血栓形成,紧急手术或抗凝治疗逆转之前。我们试图使用共振频率粘弹性测量和一次性多通道微流控盒,通过新一代全自动血栓弹力图TEG 6s评估DOAC的抗凝作用。方法9例健康男性单次口服达比加群150 mg,利伐沙班20 mg或阿哌沙班5 mg。在给予DOAC后0、1、3小时进行静脉切开术。使用TEG _ 6s测量TEG参数。使用生色测定法测量DOAC的浓度。 TEG参数与DOAC浓度相关。结果反应时间(R)显示出对DOAC摄入的最强反应。其他TEG参数与DOAC浓度之间没有相关性。使用直接凝血酶抑制剂(DTI)通道,R与达比加群水平显着相关(r?=?0.94,P?0.0001)。使用抗因子Xa(AFXa)通道,R与利伐沙班和阿哌沙班水平显着相关(r?=?0.93和r?=?0.83;两者均P?0.0001)。达比加群(DTI通道)的R> 2.5分钟,阿哌沙班(Apixaban)的> 2.5分钟和利伐沙班(AFXa通道)的> 1.8分钟与100%灵敏度和90%≥90%检测DOAC水平的特异性相关。 ≤50ng / mL。结论我们已经证明TEG _ 6s R与DOAC血药浓度具有显着相关性,并且在分析的小样本中具有以合理的灵敏度监测DOAC对止血作用的潜力。这项新技术易于在少量全血中使用,而无需专门的实验室。有必要进行进一步的研究以将R与临床结果相关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号